Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women

Endocrine-Related Cancer

Volumn 19, Issue 2, 2012, Pages 137-147

  Fourkala, Evangelia Ourania ^a   Zaikin, Alexey ^a   Burnell, Matthew ^a   Gentry Maharaj, Aleksandra ^a   Ford, Jeremy ^a   Gunu, Richard ^a   Soromani, Christina ^b   Hasenbrink, Guido ^c   Jacobs, Ian ^d   Dawnay, Anne ^b   Widschwendter, Martin ^a   Lichtenberg Fraté, Hella ^c   Menon, Usha ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTENEDIONE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ARTICLE; BIOASSAY; BREAST CANCER; CANCER RISK; CANCER SCREENING; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; POSTMENOPAUSE; RISK ASSESSMENT; UNITED KINGDOM;

AGED; ANDROSTENEDIONE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNOASSAY; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ANDROGEN; RISK ASSESSMENT; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84860910075     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0310     Document Type: Article

References (34)

1. Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN & Schairer C 2006 Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. International Journal of Cancer 119 2402-2407. (doi:10.1002/ijc.22203)
2. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD & Giles GG 2010 Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 19 492-502. (doi:10.1158/1055-9965.EPI-09-0532)
3. Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N & Hankinson SE 2006 Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). Journal of the National Cancer Institute 98 110-115. (doi:10.1093/jnci/djj011)
4. Bonofiglio D, Maggiolini M, Marsico S, Giorno A, Catalano S, Aquila S & Ando S 1999 Critical years and stages of puberty for radial bone mass apposition during adolescence. Hormone and Metabolic Research 31 478-482. (doi:10.1055/s-2007-978779)
5. Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G et al. 2006 A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Research 8 R54. (doi:10.1186/bcr1602)
6. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S & Boyle P 2003 Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 296-300. (doi:10.1016/S0140-6736(03)12342-2)
7. Eliassen AH, Missmer SA, Tworoger SS & Hankinson SE 2006 Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? Journal of Clinical Oncology 24 1823-1830. (doi:10.1200/JCO.2005.03.7432)
8. Fabian CJ & Kimler BF 2005 Selective estrogen-receptor modulators for primary prevention of breast cancer. Journal of Clinical Oncology 23 1644-1655. (doi:10.1200/JCO.2005.11.005)
9. Fox EM, Davis RJ & Shupnik MA 2008 ERbeta in breast cancer - onlooker, passive player, or active protector? Steroids 73 1039-1051. (doi:10.1016/j.steroids.2008.04.006)
10. Henderson BE & Feigelson HS 2000 Hormonal carcinogenesis. Carcinogenesis 21 427-433. (doi:10.1093/carcin/21.3.427)
11. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT et al. 2005 Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 12 1071-1082. (doi:10.1677/erc.1.01038)
12. Kalidas M & Brown P 2005 Aromatase inhibitors for the treatment and prevention of breast cancer. Clinical Breast Cancer 6 27-37. (doi:10.3816/CBC.2005.n.006)
13. Key T, Appleby P, Barnes I & Reeves G 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616. (doi: 10.1093/jnci/94.8.606)
14. Lamar CA, Dorgan JF, Longcope C, Stanczyk FZ, Falk RT & Stephenson HE Jr 2003 Serum sex hormones and breast cancer risk factors in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 12 380-383. (Pubitemid 36428000)
15. Lippman M, Monaco ME & Bolan G 1977 Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Research 37 1901-1907. (Pubitemid 8095209)
16. Maggiolini M, Donze O, Jeannin E, Ando S & Picard D 1999a Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Research 59 4864-4869. (Pubitemid 29472889)
17. Maggiolini M, Donze O & Picard D 1999b A non-radioactive method for inexpensive quantitative RT-PCR. Biological Chemistry 380 695-697. (doi:10.1515/BC.1999.086)
18. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A & Lenner P 2003 Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes & Control 14 599-607. (doi:10.1023/A:1025671317220)
19. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D et al. 2008 Recruitment to multicentre trials - lessons from UKCTOCS: descriptive study. BMJ 337 a2079. (doi:10.1136/bmj.a2079)
20. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A et al. 2009 Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology 10 327-340. (doi:10.1016/S1470-2045(09)70026-9)
21. Missmer SA, Eliassen AH, Barbieri RL & Hankinson SE 2004 Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute 96 1856-1865. (doi:10.1093/jnci/djh336)
22. Onland-Moret NC, Kaaks R, van Noord PA, Rinaldi S, Key T, Grobbee DE & Peeters PH 2003 Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. British Journal of Cancer 88 1394-1399. (doi:10.1038/sj.bjc.6600890)
23. Paris F, Servant N, Terouanne B, Balaguer P, Nicolas JC & Sultan C 2002 A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. Journal of Clinical Endocrinology and Metabolism 87 791-797. (doi:10.1210/jc.87.2.791)
24. Roy P, Franks S, Read M & Huhtaniemi IT 2006 Determination of androgen bioactivity in human serum samples using a recombinant cell based in vitro bioassay. Journal of Steroid Biochemistry and Molecular Biology 101 68-77. (doi:10.1016/j.jsbmb.2006.06.014)
25. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE et al. 2007 Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-Related Cancer 14 169-187. (doi:10.1677/ERC-06- 0045)
26. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G et al. 2009 Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiology, Biomarkers & Prevention 18 169-176. (doi:10.1158/1055-9965.EPI-08-0808)
27. Sievernich A, Wildt L & Lichtenberg-Frate H 2004 In vitro bioactivity of 17alpha-estradiol. Journal of Steroid Biochemistry and Molecular Biology 92 455-463. (doi:10.1016/j.jsbmb.2004.09.004)
28. Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA & Hankinson SE 2005 Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. Journal of the National Cancer Institute 97 595-602. (doi:10.1093/jnci/dji099)
29. Vermeulen A, Verdonck L & Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 84 3666-3672. (doi:10.1210/jc.84.10.3666)
30. Weigel MT & Dowsett M 2010 Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-Related Cancer 17 R245-R262. (doi:10.1677/ERC-10-0136)
31. Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A,Menon U, Apostolidou S, Raum E, Stegmaier C et al. 2009 Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. British Journal of Cancer 101 160-165. (doi:10.1038/sj.bjc.6605106)
32. Yager JD 2000 Endogenous estrogens as carcinogens through metabolic activation. Journal of the National Cancer Institute. Monographs 27 67-73.
33. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R & Toniolo P 2004 Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. British Journal of Cancer 90 153-159. (doi:10.1038/sj.bjc. 6601517)
34. Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I, Rinaldi S, Kaaks R & Toniolo P 2005 Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. International Journal of Cancer 114 323-327. (doi:10.1002/ijc.20694)